95.23 - 97.14
55.47 - 103.81
1.63M / 1.80M (Avg.)
55.57 | 1.74
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-82.73%
Cash & equivalents declining -82.73% while RGLD's grows 9.62%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-82.73%
Below half of RGLD's 9.62%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
-13.81%
Receivables growth 1.25-1.5x RGLD's -10.71%. Martin Whitman would worry that the company may be booking revenue too aggressively.
No Data
No Data available this quarter, please select a different quarter.
-20.26%
Higher Other Current Assets Growth compared to RGLD's zero value, indicating worse performance.
-79.67%
Below half of RGLD's 7.51%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Intangible Assets Growth compared to RGLD's zero value, indicating worse performance.
-100.00%
Higher Goodwill + Intangibles Growth compared to RGLD's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
68.91%
Above 1.5x RGLD's 22.00%. Michael Burry warns of potential hidden liabilities or intangible bloat.
68.72%
≥ 1.5x RGLD's 3.05%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
60.34%
≥ 1.5x RGLD's 4.25%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
49.06%
Similar yoy growth to RGLD's 44.99%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Tax Payables Growth compared to RGLD's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of RGLD's 144.32%. David Dodd sees fewer expansions in other current obligations.
1766.16%
Above 1.5x RGLD's 94.69%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x RGLD's -8.57%. Michael Burry sees a much bigger deferred tax load building up.
No Data
No Data available this quarter, please select a different quarter.
18192.75%
Less than half of RGLD's -2.36%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
10782.93%
Above 1.5x RGLD's 14.85%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
11.67%
Below half RGLD's 43.11%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.98%
Less than half of RGLD's -40.64%. David Dodd sees fewer intangible or market-driven swings than competitor.
-200.00%
Less than half of RGLD's 2.37%. David Dodd notes simpler yoy equity changes vs. competitor.
2.05%
0.5-0.75x RGLD's 3.46%. Martin Whitman is wary of lagging equity growth vs. competitor.
60.34%
≥ 1.5x RGLD's 4.25%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1161.42%
Less than half of RGLD's -11.88%. David Dodd sees better deleveraging or stronger cash buildup than competitor.